Oncosil Medical Ltd has released a press release.
PanCo Study Interim Analysis
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- R&D Refund - 2018 Financial Year
- IQVIA appointed EU Market Access and Reimbursement Advisor
- Preliminary Final Report
- Appendix 4C & Quarterly Update
- Response to Price Query
Later from OncoSil Medical
- CE Marking Update
- Update - CE Marking Application
- Response to ASX Price Query
- Appendix 4E and Full Year Statutory Accounts
- Receipt of $3.8M R&D Tax Incentive
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical